|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We showed that the GSD-Ib (G6pt<sup>-/-</sup>) mice manifested severe neutropenia in both blood and bone marrow, and treating G6pt<sup>-/-</sup> mice with granulocyte colony-stimulating factor (G-CSF) corrected neutropenia.
|
27864142 |
2017 |
|
Neutropenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Successful treatment of pustulosis palmaris et plantaris with granulocyte colony stimulating factor in a patient with hereditary neutropenia.
|
9885446 |
1998 |
|
Neutropenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We found a double SNP of RRM1 (2455 A>G and 2464 G>A) to be the novel haplotype that was associated with a lower frequency of chemotherapy-induced toxicity, such as neutropenia (p < .01) and G-CSF requirement (p < .005).
|
17602053 |
2007 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients received subcutaneous filgrastim as part of the prophylaxis regimen for neutropenia.
|
31623097 |
2019 |
|
Neutropenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Bone marrow progenitor cell colony-forming unit (CFU) count, serum cytokine levels, and peripheral leukocyte count after HIPEC and IP chemotherapy were compared.<b>Results:</b> Peripheral neutrophil count, cytokine (G-CSF and CXCL1/KC) levels, and bone marrow progenitor cell CFU count were significantly higher after HIPEC than after IP chemotherapy.<b>Conclusions:</b> Hyperthermia increased the serum neutrophil-recruiting cytokine levels and reduced the magnitude of chemotherapy-induced neutropenia.
|
31818168 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Very recently, it has become clear that therapeutic application of G-CSF may not be limited to different types of neutropenia, but may extend to non-hematological conditions, in particular cardiac and brain infarctions.
|
17127321 |
2007 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients received granulocyte colony-stimulating factor if they experienced grade 3/4 neutropenia or febrile neutropenia during any cycle.
|
30581162 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent studies demonstrated that granulocyte colony-stimulating factor (G-CSF), regularly used for the prevention of neutropenia, is engaged in cancer progression.
|
30147373 |
2018 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
G-CSF is now applied on a routine basis in the clinic for treatment of congenital and acquired neutropenias.
|
12687405 |
2003 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Many chemotherapy regimens used today require the support of a granulocyte-colony-stimulating factor for the prevention of life-threatening neutropenia.
|
28107322 |
2017 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Twenty-eight (19%) patients were treated with peg-filgrastim as primary prophylaxis, while 74 (64%) received filgrastim "on demand" due to neutropenia.
|
31152919 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Human recombinant granulocyte colony-stimulating factor (G-CSF) has become a treatment of choice for neutropenia of diverse etiologies.
|
9760159 |
1998 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Besides, in duration of neutropenia after the same mass injection GX-G3 showed about 3.3 days of reduction effect compared with that of filgrastim, and 1.3 days of reduction effect compared with that of pegfilgrastim in neutropenia-induced rats.
|
31294492 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prophylaxis with granulocyte colony-stimulating factor (G-CSF) reduces the severity of chemotherapy-induced neutropenia.
|
27568305 |
2017 |
|
Neutropenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Secondary objectives were to assess the influence of neutropenia on outcome of critically ill patients in prespecified subgroups (according to underlying tumor, period of admission, need for mechanical ventilation and use of granulocyte colony stimulating factor (G-CSF)).
|
30514339 |
2018 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
A slight neutropenia was present 48 hours after the application of filgrastim.
|
11005621 |
2000 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte-colony stimulating factor is the treatment of choice for neutropenia in PIDD, whereas hematopoietic cell transplantation is the only curative option.
|
23196894 |
2013 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
LA-EP2006 is a proposed biosimilar that has been developed for pegfilgrastim, a long-acting form of granulocyte colony-stimulating factor for the prevention of neutropenia.
|
28637287 |
2017 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conducted this review of neutropenia in BTHS to aid in the diagnosis of this disease, and to improve understanding of both the consequences of neutropenia and the benefits of treatment with granulocyte colony-stimulating factor (G-CSF).
|
30451719 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Treatment with granulocyte colony stimulating factor (G-CSF) is effective to increase blood neutrophils in almost all cases; this treatment is reserved, however, for patients with both neutropenia and evidence of recurrent fevers, inflammatory symptoms and infections.
|
27841775 |
2017 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte colony-stimulating factor was administered when grade 3 or 4 leukopenia and/or neutropenia occurred during radiation therapy, and no prophylactic granulocyte colony-stimulating factor was used in this study.
|
31122176 |
2018 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte-macrophage colony-stimulating factor (G-CSF) (G-CSF), cyclosporine, methylprednisolone and oral methotrexate failed to correct the neutropenia.
|
12804646 |
2003 |
|
Neutropenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Intravenous gammaglobulin did not lead to resolution of his neutropenia; G-CSF was also necessary.
|
8669967 |
1996 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte-macrophage progenitors assayed as colony-forming unit granulocyte/macrophage (CFU-GM) in spleen were markedly increased in number by Hu-G-CSF, and the accelerated recovery from neutropenia may be due to the stimulation of granulocytopoiesis by the G-CSF from progenitor cells.
|
3115920 |
1987 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients with glycogen storage disease type 1b are often treated with granulocyte colony stimulating factor (G-CSF) for prolonged periods to improve symptoms of inflammatory bowel disease (IBD) and in the face of severe neutropenia to decrease risk of infection.
|
29652549 |
2018 |